Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients

Fraser Health

Status and phase: Completed; Phase 3

Conditions: Delirium

Treatments: Drug: Sugar pill; Drug: Melatonin

Study type: Interventional

Funder types: Other

Identifiers

NCT02536417

FHREB 2015-048

Details and patient eligibility

About

The purpose of this study is to determine if melatonin administration to end-of-life patients is effective in preventing the development of delirium compared with those who do not receive this treatment. Delirium is a difficult to control symptom commonly seen in patients at the end-of-life. A person who is delirious is unable to think clearly and cannot make sense of what is going on around him/her.

Full description

All patients over the age of 19 admitted to the tertiary palliative care unit and hospice residence who could meet the study requirements will be asked within 48 hours of admission for their interest in participating in the study. All those who interested in taking part will be referred to a research nurse for initial assessment for eligibility. For eligible patients who have consented to participate in the study, a research nurse who is not directly involved in the patient's care will approach the patient. A detailed subject information containing pertinent information on the study will be provided and ample time (up to 24 hours) will be given for consideration. The research nurse will explain the consent form to the patient and obtain consent signature if he/she agrees to participate. Once formal consent obtained, the eligible patient will be enrolled in the study.

Patients will be assigned randomly to one of the two arms of the study and receive nightly doses of melatonin 0.5 mg or placebo. Patients will be monitored for 14 days or until the development of delirium or the occurrence of death.

Patients will be assessed twice a day for delirium, around the end of each nursing shift, i.e. every 12 hours (at 0330 & 1530h) for fourteen consecutive days or until the development of delirium. The diagnostic tool used to detect delirium is the Confusion Assessment Method (CAM).

The primary outcome measure is incidence of delirium, defined according to the Confusion Assessment Method (CAM).

Data on harm will be collected. For example, adverse effects from melatonin such as excessive daytime drowsiness, headaches, nausea , transient depression have been reported in the medical literature. Patients will also be monitored closely for the development any of these adverse effects during the treatment period.

Enrollment: 19 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted to the test site
• Adult patients over 19 years of age
• Patients who can provide informed consent
• Patients who are able to tolerate oral medications

Exclusion criteria

• Patients with existing delirium or dementia on admission
• Patients with poor clinical performance
• Patients taking melatonin prior to admission
• Patients taking medications that interact with melatonin
• Patients who are unable to provide informed consent
• Patients who are enrolled in any other research study involving drugs/devices

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

19 participants in 2 patient groups, including a placebo group

Treatment arm: melatonin

Active Comparator group

Description:

melatonin 0.5 mg as treatment, to be given daily at bedtime

Treatment:

Drug: Melatonin

Placebo arm

Placebo Comparator group

Description:

Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm

Treatment:

Drug: Sugar pill